Skip to main content
Dechra Pharmaceuticals PLC logo

Dechra Pharmaceuticals PLC — Investor Relations & Filings

Ticker · DPH ISIN · US2434351043 LEI · 213800J4UVB5OWG8VX82 IL Manufacturing
Open in API
Filings indexed 1,018 across all filing types
Latest filing 2024-01-08 Major Shareholding Noti…
Country GB United Kingdom
Listing IL DPH

About Dechra Pharmaceuticals PLC

https://www.dechra.com/

Dechra Pharmaceuticals PLC is a global specialist business focused on veterinary pharmaceuticals and related products. The company's expertise encompasses the development, manufacture, marketing, and sale of high-quality veterinary medicines. Its product portfolio includes both novel and differentiated generic pharmaceuticals, with a significant focus on products for companion animals. Dechra provides solutions and support to veterinary professionals worldwide to improve animal health and welfare.

Recent filings

Filing Released Lang Actions
Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is clearly identified as an RNS (Regulatory News Service) announcement from the London Stock Exchange, indicated by the 'RNS Number' and the footer information. The content is a 'TR-1: Standard form for notification of major holdings' concerning Jefferies Financial Group Inc. crossing a threshold in Dechra Pharmaceuticals Plc. This type of filing reports changes in significant share ownership, which directly corresponds to the 'Major Shareholding Notification' definition. Therefore, the filing type code is MRQ.
2024-01-08 English
Form 8.3 - Dechra Pharmaceuticals plc
Major Shareholding Notification Classification · 98% confidence The document is explicitly titled "FORM 8.3 - Dechra Pharmaceuticals plc" and references "Rule 8.3 of the Takeover Code (the “Code”)". This form is a Public Opening Position Disclosure/Dealing Disclosure made by a person holding 1% or more interest in securities relevant to a takeover situation. This type of disclosure relates to insider trading or significant ownership changes during a takeover/merger process. This aligns most closely with the M&A Activity category (TAR) or potentially a specific type of insider dealing disclosure, but given the context of the Takeover Code and dealing disclosures related to an offer, it is a specific regulatory filing related to M&A activity. Since there is no specific code for 'Takeover Disclosure', and it details dealings (Section 3) and positions (Section 2) related to an offer, it is best classified under M&A Activity (TAR) or as a general Regulatory Filing (RNS). However, since it is a specific disclosure mandated by the Takeover Code regarding an offer, TAR is more precise than RNS, although DIRS (Director's Dealing) is for directors, and this is a major shareholder/LP. Given the options, TAR (M&A Activity) captures the context of the Takeover Code disclosure best, as these forms are triggered by offers. If TAR is too narrow, RNS is the fallback. Let's re-evaluate the definitions. DIRS is for directors. This is Millennium International Management LP. This is a major shareholder disclosure during a potential takeover. This is a specific regulatory filing related to M&A. I will classify it as TAR (M&A Activity) as it is directly tied to the Takeover Code concerning an offer.
2024-01-08 English
Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is clearly identified as an RNS (Regulatory News Service) announcement from the London Stock Exchange, indicated by the 'RNS Number' header and the concluding boilerplate text mentioning RNS and the FCA. The content itself is a 'TR-1: Standard form for notification of major holdings,' which details changes in share ownership by a major shareholder (UBS Group AG). This type of mandatory disclosure regarding significant shareholding changes falls under the category of Major Shareholding Notification (MRQ). Although it is an RNS filing, MRQ is a more specific and accurate classification than the general RNS fallback.
2024-01-08 English
Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is titled 'TR-1: Standard form for notification of major holdings' and is dated 08 January 2024, concerning Dechra Pharmaceuticals PLC. It details changes in voting rights held by JPMorgan Chase & Co., specifically reporting an acquisition or disposal of voting rights that crossed a notification threshold (Resulting situation: 8.213855%). This type of mandatory disclosure regarding changes in significant share ownership is classified as a Major Shareholding Notification. The presence of 'RNS Number' and the closing statement referencing RNS (the news service of the London Stock Exchange) confirms it is a regulatory filing, but the specific content points directly to the Major Shareholding Notification category (MRQ).
2024-01-08 English
Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is clearly identified as an 'RNS Number' filing from the London Stock Exchange. The title is 'TR-1: Standard form for notification of major holdings', and the content details an 'acquisition or disposal of voting rights' by UBS Group AG, crossing a threshold. This type of mandatory disclosure regarding changes in significant share ownership perfectly matches the definition for Major Shareholding Notification (MRQ). Although it is distributed via RNS, the specific content dictates the classification over the general RNS fallback.
2024-01-08 English
Form 8.3 - Dechra Pharmaceuticals plc
Regulatory Filings Classification · 98% confidence The document is explicitly titled 'FORM 8.3 - Dechra Pharmaceuticals plc' and references 'Rule 8.3 of the Takeover Code (the “Code”)'. This form is a Public Opening Position Disclosure or Dealing Disclosure made by a person holding 1% or more interest in relevant securities during a takeover situation. This type of mandatory disclosure regarding insider dealings or significant ownership changes during a takeover bid is highly specific. It does not fit the definitions for 10-K (Annual Report), ER (Earnings Release), IR (Interim Report), or standard DIRS (Director's Dealing, which is usually Form 3/4/5 related). Since it is a specific regulatory filing related to takeover activity, it is best classified under the most specific available category that covers insider/significant shareholder activity during a corporate action, or as a general Regulatory Filing (RNS) if no better fit exists. Given the context of takeover rules and dealing disclosures, it is a specific regulatory disclosure. While 'DIRS' covers director dealing, this is broader (any person with 1%+ interest during a takeover). 'RNS' (Regulatory Filings) is the most appropriate general category for mandatory disclosures under specific regulatory codes (like the Takeover Code) that don't map to the other specific financial report types.
2024-01-05 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.